Mn Services Vermogensbeheer B.V. increased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,563 shares of the medical research company’s stock after purchasing an additional 1,200 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Amgen were worth $22,665,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of AMGN. Columbia Asset Management increased its holdings in Amgen by 10.4% during the 1st quarter. Columbia Asset Management now owns 23,700 shares of the medical research company’s stock valued at $3,888,000 after acquiring an additional 2,238 shares in the last quarter. Eliot Finkel Investment Counsel LLC boosted its stake in shares of Amgen by 6.2% during the 1st quarter. Eliot Finkel Investment Counsel LLC now owns 32,305 shares of the medical research company’s stock worth $5,300,000 after purchasing an additional 1,880 shares during the last quarter. SRS Capital Advisors Inc. boosted its stake in shares of Amgen by 22.9% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,696 shares of the medical research company’s stock worth $278,000 after purchasing an additional 316 shares during the last quarter. Verity Asset Management Inc. acquired a new stake in shares of Amgen during the 1st quarter worth about $318,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Amgen in the first quarter worth approximately $3,281,000. Hedge funds and other institutional investors own 78.46% of the company’s stock.
AMGN has been the topic of several research analyst reports. Vetr cut shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price on the stock. in a research report on Wednesday, January 3rd. Mizuho reissued a “buy” rating and issued a $198.00 target price (up from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. BMO Capital Markets reaffirmed a “hold” rating and set a $198.00 price target on shares of Amgen in a research report on Friday, October 20th. Finally, Jefferies Group reiterated a “buy” rating and set a $200.00 price objective on shares of Amgen in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $190.15.
Amgen, Inc. (NASDAQ:AMGN) traded up $3.08 during mid-day trading on Friday, reaching $185.04. 3,082,770 shares of the company traded hands, compared to its average volume of 2,720,000. The firm has a market capitalization of $134,320.00, a P/E ratio of 16.72, a P/E/G ratio of 2.66 and a beta of 1.36. Amgen, Inc. has a 1-year low of $150.38 and a 1-year high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the prior year, the company posted $3.02 earnings per share. The company’s quarterly revenue was down .7% compared to the same quarter last year. sell-side analysts expect that Amgen, Inc. will post 12.71 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 2.85%. The ex-dividend date is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is presently 41.55%.
Amgen announced that its Board of Directors has approved a stock buyback plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.
In other news, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the completion of the transaction, the executive vice president now owns 57,631 shares in the company, valued at approximately $9,888,326.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,050 shares of company stock worth $1,225,765. Corporate insiders own 0.19% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/amgen-inc-amgn-shares-bought-by-mn-services-vermogensbeheer-b-v.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.